Fiocruz

Name

Fiocruz

Legal name

Fundação Oswaldo Cruz

Website

https://portal.fiocruz.br

Company type

Private

Founded year

1900

Operating status

Operating

Headcount range

1,001–5,000 employees

Ownership category

akta.pro rank

Product category

Public Health Research & Biomanufacturing

NAICS

Medical and Diagnostic Laboratories (6215), Medical Laboratories (621511), Scientific Research and Development Services (5417)

SIC

Biological Products, (No Disgnostic Substances) (2836), Services-Medical Laboratories (8071)

akta.pro primary industry

Microbiology & Infectious Disease Diagnostics (culture, rapid antigen, syndromic panels) (HLAAALAC)

akta.pro secondary industries

Travel & Tropical Disease Vaccines (HLAIAEAE), Immunization & Vaccine Access Partnerships (Global Vaccine Alliances) (HLAJAOAF), Infectious Disease POCT (Respiratory, STI, HIV, Sepsis) (HLAHAOAA)

Keywords

• Public health research
• Vaccine manufacturing
• Biopharmaceutical production
• Genomic surveillance
• Health technology training

Headquarters

HQ city

Rio De Janeiro

HQ country

Brazil

HQ region

Latin America

Offices17 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Technology or R&D, Infrastructure, Operations, Supply Chain

Revenue model

1. Public Health System Supply: Fiocruz receives government funding to produce vaccines, medications, and health technologies for Brazil's Unified Health System (SUS)
2. Technology Transfer and Partnerships: Strategic partnerships with international biotech companies (WuXi Biologics, GC MS) for technology transfer and domestic production development
3. Research Grants and International Funding: Funding from international organizations including WHO for training initiatives and regional health programs

Go-to-market motion1 record

Distribution channels3 records

Marketing channels4 records

Core offering

Fiocruz (Fundação Oswaldo Cruz) is a Brazilian public health research institution that conducts biomedical, genomic, and clinical research across 16 technical-scientific units, manufactures vaccines and biopharmaceuticals through its Bio-Manguinhos and Farmanguinhos divisions, operates a national genomic surveillance network (Rede Genômica Fiocruz), provides respiratory and infectious disease surveillance platforms (InfoGripe, Observatório Covid-19), and delivers health-focused education and training programs through Campus Virtual Fiocruz and the Canal Saúde media outlet.

Product overview

Fiocruz (Fundação Oswaldo Cruz) is Brazil's premier public health institution operating as a complex ecosystem of 16 technical-scientific units focused on teaching, research, innovation, healthcare assistance, technological development, and extension services. The institution functions as a vertically integrated health system combining vaccine and pharmaceutical manufacturing (Bio-Manguinhos and Farmanguinhos), genomic surveillance (Rede Genômica Fiocruz), epidemiological monitoring platforms (InfoGripe, Observatório Covid-19), scientific computing infrastructure (PROCC), health data analytics (PCDAS), and educational platforms (Campus Virtual Fiocruz). The portfolio also includes science communication through Canal Saúde, Editora Fiocruz publishing, and the Museu da Vida science museum. Regional institutes extend Fiocruz's presence across Brazil (Fiocruz Amazônia, Fiocruz Minas, Fiocruz Pernambuco, Fiocruz Paraná) and internationally (Fiocruz África).

Differentiator

Problem solved

Functional benefit

Brands

• Bio-Manguinhos: Instituto de Tecnologia em Imunobiológicos - produces vaccines and immunobiologicals
• Farmanguinhos
• Campus Virtual Fiocruz
• Museu da Vida Fiocruz
• Canal Saúde
• Editora Fiocruz

Products and services

• Bio-Manguinhos (Vaccine Manufacturing) Manufactures vaccines and biologics (including Yellow Fever and COVID-19 vaccines) for distribution through Brazil's public health system (SUS) and through technology transfer partnerships with international manufacturers.
• Farmanguinhos (Pharmaceutical Production) Manufactures essential medicines, antiretrovirals, and other pharmaceutical products for the Brazilian public health system.
• Rede Genômica Fiocruz (Genomic Surveillance Network) Coordinates a national network for genomic surveillance of pathogens, including SARS-CoV-2, providing sequencing capacity and epidemiological intelligence to Brazil's public health authorities.
• InfoGripe (Respiratory Infection Surveillance) Public surveillance platform monitoring severe acute respiratory infections (SARIs) and influenza-like illness across Brazil, providing data to public health authorities and the general public.
• Campus Virtual Fiocruz Online learning platform delivering health-focused specializations, open courses, MOOCs, and training programs for health professionals, researchers, and the general public.
• Observatório Covid-19 Fiocruz Epidemiological observatory that tracks COVID-19 hospitalizations, severe acute respiratory infections, vaccination coverage, and other pandemic indicators across Brazil.
• Instituto Nacional de Infectologia Evandro Chagas (INI) National reference institute providing clinical care, clinical research, and training in infectious diseases including HIV/AIDS, tuberculosis, viral hepatitis, and tropical diseases.
• Instituto Nacional de Saúde da Mulher, da Criança e do Adolescente Fernandes Figueira (IFF) National reference hospital, research, and teaching institute specialized in women's, children's, and adolescent health, offering clinical services and residency programs.
• Banco de Leite Humano (Human Milk Bank Network) National reference center and network for human milk banking, supporting neonatal intensive care units across Brazil with pasteurized donor human milk and lactation support.
• Instituto Nacional de Controle de Qualidade em Saúde (INCQS) National reference laboratory providing quality control testing and analytical services for medicines, vaccines, diagnostic kits, cosmetics, sanitizers, and other health products in Brazil.
• Canal Saúde Television, web, and social media channel producing and broadcasting public health content, documentaries, and educational programming.
• Editora Fiocruz Academic publishing house producing scientific books, textbooks, and journals in public health, biomedical sciences, and the history of science.
• Museu da Vida Fiocruz Interactive science museum offering exhibits, educational programs, and science communication activities to promote public understanding of science and health.
• VideoSaúde Distribuidora Distribution service for audiovisual public health content, providing videos, documentaries, and educational materials to broadcasters, educators, and researchers.

Quantifiable outcome

• WHO designated as regional biomanufacturing training center for the Americas
• +2 more outcomes

Named customers2 records

Segments3 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

Eleven partnerships are on record, tiered core and major.

• World Health Organization (WHO)coreStrategic or Co-development Partner · 15 June 2026WHO designated Fiocruz as the regional biomanufacturing training center for the Americas, part of the WHO Biomanufacturing Workforce Training Initiative launched in 2023. The designation aims to support sustainable regional manufacturing capacity for health technologies across the Americas by training workforces in biomanufacturing skills.
• Pontificia Universidad Católica de Chile (UC Chile)majorStrategic or Co-development Partner · 5 June 2026Joint 12-month research project titled 'Enhancing Pathology through Quantum Computing' to develop hybrid quantum algorithms for biomedical image analysis using quantum machine learning and NVIDIA CUDA-Q platform. Project focuses on renal pathology and involves researchers from Fiocruz and UFBA.
• Thermo Fisher ScientificmajorTechnology or Integration · 1 June 2026Fiocruz and Thermo Fisher Scientific signed memorandum of understanding to impulsionar inovação (drive innovation) in health sector through technology access and collaboration.
• BeOnemajorStrategic or Co-development Partner · 1 June 2026Fiocruz and BeOne signed memorandum of understanding to impulsionar innovation in health. The agreement creates the basis for constructing solutions for complex health challenges.
• PfizermajorStrategic or Co-development Partner · 16 April 2026Partnership between Pfizer Inc and Fiocruz in Brazil for the tofacitinib market, part of global pharmaceutical collaborations targeting the Brazilian market.
• WuXi BiologicscoreTechnology or Integration · 30 March 2026Fiocruz and Chinese biotech company WuXi Biologics signed a memorandum of understanding focused on creating technological capabilities and strengthening Brazil's health industrial base. The agreement was formalized during an official mission to China led by Minister of Health Alexandre Padilha.
• GEMMABiocoreStrategic or Co-development Partner · 26 February 2026Public-private partnership for gene therapy clinical trials for Spinal Muscular Atrophy Type 1 (SMA1) using GB221 therapy. The trial is being conducted in Brazil through a public-private partnership with Fiocruz, with ANVISA approval obtained in late 2025. US FDA granted rare pediatric disease designation.
• GC MS (GC Biopharma)majorTechnology or Integration · 24 February 2026GC MS, a subsidiary of GC Biopharma's in vitro diagnostics division, signed an MoU with Fiocruz at the Korea-Brazil Business Forum. The partnership aims to jointly develop reagents and transfer technology in immunology and biochemistry diagnostics, establish point-of-care testing solutions, and create new products.
• China (Ministry/Health Institutions)coreStrategic or Co-development Partner · 16 October 2025Brazil and China signed MoU in Beijing to expand medical research and treatment options in Brazil's public health system (SUS). Includes developing therapies for cancer, obesity, diabetes, and autoimmune diseases, and aims to produce insulin glargine domestically in Brazil.
• Birmex (Mexico)coreStrategic or Co-development Partner · 25 August 2025Brazil and Mexico signed dual MoUs in August 2025 establishing a regulatory and production alliance. Birmex and Fiocruz will jointly produce vaccines, pharmaceutical ingredients, and treatments including dengue therapies and mRNA vaccine technology. Initiative seeks to reduce dependence on external supply chains and strengthen health sovereignty.
• UN FoundationmajorStrategic or Co-development Partner · 28 October 2024UN Foundation, National Academy of Medicine, Fiocruz, and Global Pandemic Monitoring Board co-convened workshop on pandemic risk assessment intersecting with climate change in Rio de Janeiro, Brazil. Part of efforts to advance pandemic risk assessment frameworks.

Scale indicators4 records

Recent moves7 records

Expansion highlights5 records

Direct peers

• Birmex: Mexico's state-owned biological and reagent laboratories, designated as Fiocruz's partner for joint vaccine and pharmaceutical production under the Brazil-Mexico alliance. Both are public-sector vaccine/biologic manufacturers serving national health systems with analogous institutional profiles.
• Instituto Butantan: Brazil's other major public-sector vaccine and biopharmaceutical producer, operating under the São Paulo state government. Directly comparable as a domestic public health manufacturer competing with Fiocruz in supplying SUS with vaccines, antivenoms, and biologics.
• Bio-Manguinhos (sub-brand): Fiocruz's own immunobiologicals institute, but operationally comparable to standalone public-sector vaccine manufacturers like Instituto Butantan and Bharat Biotech in scale, technology platform, and public health supply mandate.

Broad incumbents

• National Institutes of Health (NIH): US federal agency conducting and supporting biomedical and public health research at massive scale. Comparable as the largest government-funded public health research enterprise, with analogous structure of research institutes, training programs, and international cooperation activities.
• Pasteur Institute: French non-profit foundation and global reference public health research institution with comparable mandate across infectious disease research, vaccine development, epidemiological surveillance, and international training — a structurally similar public health foundation operating across multiple countries.
• Centers for Disease Control and Prevention (CDC): US federal public health agency with comparable mandate in infectious disease surveillance, epidemiological monitoring (parallel to InfoGripe and Rede Genômica), and global health partnerships through WHO/PAHO frameworks.
• Serum Institute of India: World's largest vaccine manufacturer by doses, supplying global immunization programs including low- and middle-income countries. Comparable as a high-volume, public-health-oriented vaccine producer, though structured as a private company rather than government foundation.
• China National Center for Disease Control and Prevention: China's national public health agency with parallel functions in disease surveillance, vaccine policy, and biomanufacturing oversight. Comparable as a counterpart public health authority and increasingly a partner institution through the MoU on insulin glargine production.

Regional players

• South African Medical Research Council (SAMRC): South Africa's statutory body for health research funding and coordination, with comparable mandate in biomedical research capacity building for an African context. Relevant given Fiocruz's Fiocruz África initiative and emerging Africa cooperation portfolio.
• Indian Council of Medical Research (ICMR): India's apex public health research body coordinating biomedical research, vaccine development, and infectious disease surveillance across a population of 1.4B. Comparable to Fiocruz as a government-funded public health research umbrella, though larger in scope and operating in a different geography.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks5 records

Key highlights6 records

Customer concentration

• Xx.com/fiocruz
• YouTubeyoutube.com/user/fundacaooswaldocruz
• Facebookfacebook.com/pages/Funda%C3%A7%C3%A3o-Oswaldo-Cruz-Fiocruz/331204146937753
• LinkedInlinkedin.com/company/fiocruz
• Instagraminstagram.com/oficialfiocruz

Revenue estimate

Valuation estimate

Number of profiles

Subsidiaries15 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Fiocruz